Looking for a Mounjaro Equivalent? Here Is What Exists in the UK

Why 'equivalent' is harder to answer than it looks

Most people searching for a Mounjaro equivalent are really asking one of two things: is there a cheaper version of the same drug, or is there another medicine that works similarly? Both are fair questions, and both deserve a straight answer.

On the first point: there is currently no licensed generic tirzepatide in the UK. Eli Lilly holds the patent, and Mounjaro is sold under one brand name at one licensed specification. If you see anything marketed as generic tirzepatide or a substitute pen, it has not been through MHRA licensing, that matters enormously for safety.

On the second point: the medicine most often described as a tirzepatide equivalent is semaglutide, sold for weight loss as Wegovy. Both slow gastric emptying, reduce appetite and are given as once-weekly injections. The difference is in the receptor targets. Tirzepatide engages both the GIP and GLP-1 pathways; semaglutide targets GLP-1 alone. That pharmacological distinction translates into a measurable difference in the trial evidence, SURMOUNT-5, published in the New England Journal of Medicine in 2025, found that tirzepatide produced greater average weight loss than semaglutide 2.4mg in a direct head-to-head comparison over 72 weeks. Neither medicine is right for everyone, though, and a greater average result in a trial is not the same as a guaranteed better result for a given individual.

There is also now a third licensed option worth knowing about: Wegovy tablets (oral semaglutide), approved by the MHRA in June 2026 as the first oral GLP-1 medicine licensed in the UK for weight management. It suits people who prefer not to inject. It works through the same single GLP-1 pathway as the injection, and the trial evidence shows around 13.6% average weight loss over 64 weeks, lower on average than tirzepatide, but a meaningful result for many people and a genuinely different format.

What the clinical trial numbers actually mean for this decision

It is worth pausing on what trial averages do and do not tell you. SURMOUNT-1 (a large randomised trial of tirzepatide published in the New England Journal of Medicine) reported around 20–21% average body-weight reduction at the 15mg maintenance dose over 72 weeks. The STEP 1 trial for semaglutide 2.4mg, run over a similar period, reported around 15% average reduction. SURMOUNT-5 then compared them directly and confirmed tirzepatide's edge.

Averages, though, conceal a wide spread of individual responses. Some people do very well on semaglutide; some find tirzepatide's side-effect profile harder to tolerate at higher doses. A prescriber weighs your starting BMI, any relevant health conditions, your history with other medicines and your own preferences, none of which a trial average captures.

The cost of treatment is also part of the decision for most people. Tirzepatide's UK list price rose significantly from September 2025, and private prices for both medicines vary by dose and provider. Understanding the full picture (including what a quoted price actually includes) matters before committing to either.

One quick habit worth building: before using any online pharmacy for a prescription medicine, spend thirty seconds checking it on the GPhC pharmacy register. If it is not there, do not order from it.

Who the licensed alternatives are actually suitable for

Both Mounjaro and Wegovy are licensed for adults with a BMI of 30 or above, or from 27 upwards if a weight-related health condition is present, conditions such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance. Neither medicine is licensed for under-18s, and neither is recommended during pregnancy, breastfeeding or when actively trying to conceive.

There are also condition-specific factors that a prescriber must consider. People with a personal or family history of certain thyroid conditions, or a history of pancreatitis, may not be suitable candidates for either medicine. That is exactly why these are prescription-only: suitability is individual, not universal.

NICE's appraisal of tirzepatide (TA1026) sets out the criteria for NHS access, which are currently narrower than the licensed population. The full tirzepatide overview on our site covers the NHS phased rollout in detail. For private treatment, the licensed eligibility criteria apply, and a prescriber reviews the complete picture before recommending anything.

If you are currently on semaglutide and wondering whether tirzepatide is a suitable next step (or vice versa) that conversation belongs with a prescriber who can look at your response so far, your current dose and your broader health history, including side effects such as frequent urination that some people notice on Mounjaro. The Mounjaro treatment page sets out how that assessment works in practice.

Medicines sometimes confused with Mounjaro equivalents

A few names come up regularly in this context and are worth clearing up. Ozempic is also semaglutide, but it is licensed in the UK for type 2 diabetes, not weight loss. Rybelsus is oral semaglutide in the 3, 7 and 14mg strengths, again for diabetes. Zepbound is the US brand name for tirzepatide and does not exist as a UK product. None of these is an equivalent to Mounjaro for weight management in UK clinical practice.

Saxenda (liraglutide) is a GLP-1 injection that is licensed for weight management in the UK, though the evidence places it behind both tirzepatide and semaglutide 2.4mg in terms of average weight reduction. Orlistat, which works differently by reducing fat absorption rather than acting on hunger hormones, is sometimes raised in this context too, it is an older option with a different side-effect profile and is available at lower prescription threshold.

The frequently asked questions section of our site addresses several of these comparisons, including guidance on Mounjaro 2mg as the starting dose for new patients. For anything more specific to your own situation, our clinical team reviews consultations the same day, and the process starts with a free assessment, no commitment required. Check your eligibility at our treatments page.